Background: Right ventricular (RV) function plays a pivotal role in advanced heart failure patients, especially for screening those who may benefit from left ventricular assist device (LVAD) implantation. We introduce RV contraction pressure index (RVCPI) as a new echo-Doppler parameter of RV function. The accuracy of RVCPI in detecting RV failure was compared with the criterion standard, the RV stroke work index (RVSWI) obtained through right heart catheterization in advanced heart failure patients referred for heart transplantation or LVAD implantation.
Methods And Results: Right heart catheterization and echo-Doppler were simultaneously performed in 94 consecutive patients referred to our center for advanced heart failure (ejection fraction (EF) 24 ± 8.8%, 40% NYHA functional class IV). RV stroke volume and invasive pulmonary pressures were used to obtain RVSWI. Simplified RVCPI (sRVCPI) was derived as TAPSE × (RV - right atrial pressure gradient). Close positive correlation between sRVCPI and RVSWI was found (r = 0.68; P < .001). With logistic regression, we found that increased sRVCPI showed an independent reduced risk (odds ratio 0.98, 95% confidence interval [CI] 0.97-0.99; P = .016) for patients to present a depressed RVSWI (<0.25 mm Hg/L·m(2)). Simplified RVCPI showed high diagnostic accuracy (area under the receiver operating characteristic curve 0.94, 95% CI 0.89-0.99) and good sensitivity and specificity (92% and 85%, respectively) to predict depressed RVSWI with the use of a cutoff value of <400 mm·mm Hg.
Conclusions: In patients with advanced heart failure, the new simple bedside sRVCPI closely correlated with RVSWI, providing an independent, noninvasive, and easy tool for the evaluation of RV function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cardfail.2012.10.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes and Impact of Device Iterations in Mitral Valve Transcatheter Edge-to-Edge Repair: The REPAIR Study.
JACC Cardiovasc Interv
November 2024
Department of Cardiology, Heart Center, Faculty of Medicine, University of Cologne, Cologne, Germany. Electronic address:
Background: The PASCAL P10 system for mitral valve transcatheter edge-to-edge repair has undergone iterations, including introduction of the narrower Ace implant and the Precision delivery system.
Objectives: The study sought to evaluate outcomes and the impact of PASCAL mitral valve transcatheter edge-to-edge repair device iterations.
Methods: The REPAIR (REgistry of PAscal for mltral Regurgitation) study is an investigator-initiated, multicenter registry including consecutive patients with mitral regurgitation (MR) treated from 2019 to 2024.
Early Identification of Myocardial Microstructural Alterations in Hypertrophic Cardiomyopathy with in Vivo Cardiac Diffusion-Tensor Imaging.
Radiol Cardiothorac Imaging
February 2025
From the Department of Magnetic Resonance Imaging, Radiology Imaging Center, Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road No. 167, Xicheng District, Beijing 100037, China (Z.D., Y.T., G.Y., X.M., S.Y., J.W., X.X., K.Y., M.L., X.C., S.Z.); Clinical and Technical Support, Philips Healthcare, Beijing, China (P.S.); and Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, SZ University Town, Shenzhen, China (K.Z., Y.Z.).
Purpose To explore the diffusion characteristics of hypertrophic cardiomyopathy (HCM) using in vivo cardiac diffusion-tensor imaging (cDTI) and to determine whether cDTI could help identify abnormal myocardium beyond cardiac MRI findings of fibrosis and hypertrophy. Materials and Methods In this prospective study conducted from April to August 2023, participants with HCM and healthy volunteers were enrolled for cardiac MRI evaluation, including cine, late gadolinium enhancement (LGE), T1 mapping, and cDT imaging, using a 3.0-T scanner.
View Article and Find Full Text PDFHypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with an increased risk of arrhythmias, heart failure, and sudden cardiac death. Current imaging and clinical markers are not fully sufficient in accurate diagnosis and patient risk stratification. Although known cardiac biomarkers in blood are used, they lack specificity for HCM and primarily stratify for death due to heart failure in overt cases.
View Article and Find Full Text PDFAdvanced Lung-on-a-Chip Technology: Mimicking the Complex Human Lung Microenvironment.
Int J Biol Sci
January 2025
Division of Science Education, Kangwon National University, 24341, Republic of Korea.
Intricate crosstalk among various lung cell types is crucial for orchestrating diverse physiological processes. Traditional two-dimensional and recent three-dimensional (3D) assay platforms fail to precisely replicate these complex communications. Many lung models do not effectively reflect the multicellular complexity of lung tissue.
View Article and Find Full Text PDFRefining cardiac resynchronization therapy: a comprehensive review on the role of advanced multimodality imaging.
Front Cardiovasc Med
December 2024
Department of Cardiology, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Cardiac resynchronization therapy (CRT) offers significant benefits in symptom alleviation, reduction of rehospitalization rates, and overall survival of patients with heart failure (HF) with reduced ejection fraction (rEF). However, despite its proven efficacy, precisely identifying suitable CRT candidates remains a challenge, with a notable proportion of patients experiencing non-response. Accordingly, many attempts have been made to enhance patient selection, and to identify the best imaging parameters to predict the response and survival after CRT implantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!